Substrate dependency of C19 conjugates in hirsute hyperandrogenic women and the influence of adrenal androgen. 1995

E Carmina, and E Gentzschein, and F Z Stanczyk, and R A Lobo
Cattedra di Endocrinologia, Universita di Palermo, Italy.

Serum C19 conjugates, specifically 3 alpha-androstanediol glucuronide (3 alpha G), reflect peripheral androgen action through the action of 5 alpha-reductase activity. The origin of 5 alpha-reduced C19 conjugates has been controversial and it has been suggested that they are derived primarily from adrenal androgens. We examined concentrations of 3 alpha G, 3 alpha-androstanediol sulphate (3 alpha S), androsterone glucuronide (AoG) and androsterone sulphate (AoS) in 40 hirsute hyperandrogenic women. These patients were divided into four groups based upon individual, combined or normal concentrations of the adrenal androgens dehydroepiandrosterone (DHEAS) and 11 beta-hydroxy-androstenedione. Testosterone, unbound testosterone and androstenedione were similar in these groups. Serum 3 alpha G was equally high in all groups and was correlated significantly with hirsutism, while the other conjugates were not. Androsterone glucuronide was raised in all groups but was higher in patients with raised DHEAS. Serum 3 alpha S was raised in all groups and was higher where both adrenal androgens were raised. Serum AoS was highly correlated with DHEAS. Serum 3 alpha G was correlated with unbound testosterone and androstenedione but not with the adrenal androgens. The glucuronide conjugates were correlated with one another as were the sulphate conjugates but glucuronides and sulphates were not correlated. These data confirm ovarian and adrenal dependency of C19 conjugates. Serum 3 alpha G appears to reflect hirsutism most accurately and is least dependent on adrenal androgens in patients with mixed hyperandrogenism.

UI MeSH Term Description Entries
D005260 Female Females
D006628 Hirsutism A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000311 Adrenal Glands A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS. Adrenal Gland,Gland, Adrenal,Glands, Adrenal
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen
D000738 Androsterone A metabolite of TESTOSTERONE or ANDROSTENEDIONE with a 3-alpha-hydroxyl group and without the double bond. The 3-beta hydroxyl isomer is epiandrosterone. 3-alpha-Hydroxy-5-alpha-Androstan-17-One,5 alpha-Androstan-3 alpha-ol-17-one,Epiandrosterone,3 alpha Hydroxy 5 alpha Androstan 17 One,5 alpha Androstan 3 alpha ol 17 one
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D015113 Androstane-3,17-diol The unspecified form of the steroid, normally a major metabolite of TESTOSTERONE with androgenic activity. It has been implicated as a regulator of gonadotropin secretion. 5 Androstane 3,17 diol,5 alpha-Androstane-3 alpha,17 beta-diol,5 alpha-Androstane-3 beta,17 alpha-diol,5 alpha-Androstane-3 beta,17 beta-diol,5 alpha-Androstane-3alpha,17 beta-diol,5 beta-Androstane-3 alpha,17 beta-diol,5-Androstane-3,17-diol,5alpha-Androstane-3beta,17alpha-diol,5 alpha Androstane 3 alpha,17 beta diol,5 alpha Androstane 3 beta,17 alpha diol,5 alpha Androstane 3 beta,17 beta diol,5 alpha Androstane 3alpha,17 beta diol,5 beta Androstane 3 alpha,17 beta diol,5alpha Androstane 3beta,17alpha diol,Androstane 3,17 diol
D017588 Hyperandrogenism A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.

Related Publications

E Carmina, and E Gentzschein, and F Z Stanczyk, and R A Lobo
January 2014, The Journal of steroid biochemistry and molecular biology,
E Carmina, and E Gentzschein, and F Z Stanczyk, and R A Lobo
January 1983, American journal of obstetrics and gynecology,
E Carmina, and E Gentzschein, and F Z Stanczyk, and R A Lobo
May 1998, Fertility and sterility,
E Carmina, and E Gentzschein, and F Z Stanczyk, and R A Lobo
May 1975, American journal of obstetrics and gynecology,
E Carmina, and E Gentzschein, and F Z Stanczyk, and R A Lobo
January 1974, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
E Carmina, and E Gentzschein, and F Z Stanczyk, and R A Lobo
December 1989, American journal of obstetrics and gynecology,
E Carmina, and E Gentzschein, and F Z Stanczyk, and R A Lobo
May 1986, Clinics in endocrinology and metabolism,
E Carmina, and E Gentzschein, and F Z Stanczyk, and R A Lobo
January 1972, The Journal of clinical endocrinology and metabolism,
E Carmina, and E Gentzschein, and F Z Stanczyk, and R A Lobo
June 1980, Clinical endocrinology,
E Carmina, and E Gentzschein, and F Z Stanczyk, and R A Lobo
February 2007, Journal of endocrinological investigation,
Copied contents to your clipboard!